REHOVOT, Israel, November 3 Foamix Ltd, a global leaderin the development of dermatological foam medications today announced thatthe company has extended its agreement with Galderma to develop an innovativemedicated foam for an additional dermatological indication. This newtreatment contains a novel drug for the therapy of certain skin diseases.
Under this agreement, Foamix will develop the foam formulation of theproduct and Galderma will subsequently conduct all other activities(clinical, non-clinical, etc). Foamix will receive staged payments onsuccessful completion of the technical milestones of the project.
Headquartered in Rehovot, Israel, Foamix Ltd. is a leading developer oftopical and mucosal foams for dermatological and gynecological applications.Foamix's state-of-the-art foams provide controlled delivery of a variety ofactive ingredients. Foamix is currently collaborating with major, medium andsmall pharmaceutical and cosmetic companies on a plurality of projects in thedevelopment of proprietary dermatological and gynecologic foam drugs.Additionally, the Company has an in-house pipeline of dermatological andgynecological drugs in foam presentation.
To date, Foamix has seventeen issued patents worldwide covering its foamand OilGel technology platforms and in excess of 150 pending applications ofwhich more than a third are filed in the United States. The Company employs aleading U.S. patent counsel (WilmerHale LLC).
For additional information, please visit http://www.foamix.co.il.
Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 email@example.com
SOURCE Foamix Ltd